Can you get Mounjaro with a BMI of 27?

Does the UK licence actually allow Mounjaro at BMI 27?

A common assumption is that you need a BMI of at least 30 to be considered for any weight-loss medicine. That's understandable, 30 is the standard threshold for Mounjaro when no other conditions are present. But the licensed indication is wider than that. The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, covers adults with a BMI of 27 or above when a weight-related health condition is also present. If you want a detailed breakdown of how that threshold works in practice, our page on Mounjaro at BMI 27 walks through the licensed criteria and what meeting them actually involves. So a BMI of exactly 27 sits within the licence, provided that second criterion is met.

Weight-related conditions that typically count include type 2 diabetes, prediabetes, high blood pressure, high cholesterol (dyslipidaemia), obstructive sleep apnoea and similar cardiometabolic diagnoses. Osteoarthritis is also cited in UK clinical guidance. If you have one of those conditions documented, the BMI-27 route is a legitimate one. Getting Mounjaro with a BMI under 30 is a related question our prescribers field regularly, and the answer turns on exactly this point: what else is going on clinically.

It is also worth knowing that UK guidance uses a lower BMI threshold for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds (typically 2.5 kg/m² below the headline figures) because cardiometabolic risk runs higher at lower measured BMIs in those populations. If that applies to you, a BMI marginally below 27 might still fall within scope. A prescriber will factor this in.

What does a prescriber actually weigh up at this BMI?

Eligibility is not a box-ticking exercise. When your consultation arrives at our pharmacy, a named GPhC-registered prescriber reads your answers (not a piece of software) and considers several things together. The BMI figure is a starting point, not a verdict.

They will look at the nature and severity of any comorbidities, your medical history, current medications (some affect absorption; some are contraindicated), and whether the likely benefit of treatment outweighs the risks for you specifically. Contraindications listed in the Mounjaro SmPC include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and a history of pancreatitis; these would need to be discussed openly.

At BMI 27, the margin for clinical benefit is real but the prescriber will want to be confident it is there. That's not a barrier designed to exclude people; it reflects what responsible prescribing looks like for a medicine that requires ongoing monitoring and dose titration. Our clinical team takes this assessment seriously precisely because these medicines are powerful and the starting dose matters.

If you are currently using Mounjaro through another provider and want to transfer, you will be asked to provide evidence of your current treatment and dose before any continuation is approved. That protects you as much as it does us.

How does NICE guidance compare to the licensed criteria at this BMI?

NICE's technology appraisal TA1026, which governs NHS access to tirzepatide, sets considerably stricter criteria than the private licence: a BMI of 35 or above plus at least one qualifying condition, and the medicine used within a specialist weight management service. At BMI 27, you would not qualify for tirzepatide through the NHS under the current phased rollout, regardless of how many conditions you have.

That gap between what the licence permits and what the NHS currently funds is precisely why private routes exist. Qualifying for Mounjaro at BMI 27 privately is a realistic prospect if the clinical criteria are met; doing so through the NHS at this BMI is not currently possible. The Mounjaro treatment page outlines how the private route works in practice.

For context on the cost of private treatment, our page on Eli Lilly's UK price changes explains how market pricing has moved and what transparent pricing from a regulated pharmacy should include. The short version: any legitimate private price covers your prescription, clinical assessment and dispensing, not just the pen itself.

What happens next if you think you might qualify?

If your BMI is around 27 and you have a documented weight-related condition, the most useful next step is a clinical consultation. Our free consultation asks about your health history, current conditions and medications; a GPhC-registered prescriber then reviews the full picture the same day. If treatment is clinically appropriate, it is dispensed from our own GPhC-registered pharmacy and delivered free the next working day in plain, unbranded packaging.

If treatment is not appropriate, you will be told why, clearly, by a clinician. No pressure, no upsell. You can also look at our weight management treatment overview to understand what options exist across different eligibility profiles, or read the frequently asked questions if you have more specific queries before starting. For anything urgent or outside the scope of a standard consultation, our team is reachable via our contact page. The about us page sets out who we are and how our pharmacy is regulated, if you want to check credentials before proceeding.

The NHS BMI calculator at nhs.uk is worth using if you are unsure of your current figure, it takes height and weight and gives an immediate result. And the NICE appraisal TA1026 is publicly available if you want to read the formal clinical criteria in full.